Related Experiment Video
Updated: Aug 19, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Sequential EGFR inhibition sensitizes glioblastoma to temozolomide
Xiaozhou Yu1, Runxin Wu1, Shi-Yuan Cheng1
1The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, the Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Abstract:
Glioblastoma (GBM) remains a devastating disease for which standard temozolomide chemotherapy is limited by O6-methylguanine-DNA methyltransferase (MGMT)-mediated DNA damage repair. By targeting epidermal growth factor receptor (EGFR), a major oncogenic driver of GBM, Guo, Habib, and colleagues demonstrate that EGFR inhibition prior to temozolomide treatment induces an adaptive response that downregulates MGMT, enhancing therapeutic efficacy.
Insights
Glioblastoma treatment is improved by targeting epidermal growth factor receptor (EGFR) before chemotherapy. This approach downregulates O6-methylguanine-DNA methyltransferase (MGMT), enhancing temozolomide efficacy against brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Targeted Therapy
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Standard temozolomide chemotherapy efficacy is often restricted by DNA repair mechanisms.
- O6-methylguanine-DNA methyltransferase (MGMT) is a key enzyme in temozolomide resistance.
Purpose of the Study:
- To investigate the impact of epidermal growth factor receptor (EGFR) inhibition on MGMT expression in GBM.
- To determine if EGFR inhibition can sensitize GBM to temozolomide therapy.
- To explore adaptive resistance mechanisms in glioblastoma treatment.
Main Methods:
- Utilized targeted inhibition of EGFR in glioblastoma models.
- Assessed changes in MGMT expression following EGFR inhibition.
- Evaluated the combined efficacy of EGFR inhibition and temozolomide treatment.
Main Results:
- EGFR inhibition induced an adaptive response in glioblastoma cells.
- This adaptive response led to the downregulation of MGMT.
- Combined EGFR inhibition and temozolomide treatment demonstrated enhanced therapeutic efficacy.
Conclusions:
- Targeting EGFR prior to temozolomide represents a promising strategy for GBM treatment.
- Downregulation of MGMT via EGFR inhibition overcomes a key resistance mechanism.
- This approach holds potential for improving outcomes in glioblastoma patients.
